Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20269092 | 0.94 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29928 | 0.89 | MAPT (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL20268590 | 0.88 | ALDH1A1 (0.39) | CA1CA2CA7CA9CA12 | |
| SCHEMBL11870432 | 0.88 | TP53 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL21809265 | 0.88 | NQO2 (0.38) | CA1CA2CA7CA9CA12 | |
| Hydrochloric Acid SCHEMBL11483295 | 0.88 | MAPT (0.48) | CA1CA2CA7CA9CA12 | |
| Water SCHEMBL11712599 | 0.88 | MAPT (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL11713103 | 0.88 | MAPT (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL21809260 | 0.86 | KMT2A (0.36) | CA1CA2CA7CA9CA12 | |
| Water SCHEMBL11717659 | 0.86 | MAPT (0.47) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958842-B2 | Substituted phenazines and methods of treating cancer and bacterial diseases | ADJUTEC PHARMA AS (NO) | 2024-04-16 | — | — | US | disclosed |
| US-20210292313-A1 | SUBSTITUTED PHENAZINES AND METHODS OF TREATING CANCER AND BACTERIAL DISEASES | Rongved, Pål (NO) | 2021-09-23 | — | — | US | disclosed |
| US-11046678-B2 | Substituted phenazines and methods of treating cancer and bacterial diseases | Rongved, Pål (NO) | 2021-06-29 | — | — | US | disclosed |
| US-20200095237-A1 | COMPOUNDS | Rongved, Pål (NO) | 2020-03-26 | — | — | US | disclosed |
| US-9745273-B2 | Phenazine derivatives as anti-neoplastic agents and anti-infective agents | UNIVERSITETET I OSLO (NO) | 2017-08-29 | — | — | US | disclosed |
| US-9745273-B2 | Phenazine derivatives as anti-neoplastic agents and anti-infective agents | UNIVERSITETET I OSLO (NO) | 2017-08-29 | — | — | US | disclosed |
| EP-3063136-A2 | PHENAZINE DERIVATIVES AS ANTI-CANCER AND ANTI-INFECTIVE AGENTS | Universitetet I Oslo (NO) | 2016-09-07 | — | — | EP | disclosed |
| US-20160251320-A1 | Compounds | UNIVERSITÉ CLAUDE BERNARD LYON 1 (FR) | 2016-09-01 | — | — | US | disclosed |
| US-20160251320-A1 | Compounds | UNIVERSITÉ CLAUDE BERNARD LYON 1 (FR) | 2016-09-01 | — | — | US | disclosed |
| WO-2015063516-A2 | COMPOUNDS | UNIVERSITETET I OSLO (NO) | 2015-05-07 | — | — | WO | disclosed |
| US-4003891-A | SOLID STATE | HOFFMANN-LA ROCHE INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-3966734-A | COMPLEXING WITH FERRIC CHLORIDE | HOFFMANN-LA ROCHE INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958842-B2 | Substituted phenazines and methods of treating cancer and bacterial diseases | TLR5, TOP2A, SCN5A | CA1 3541/4885CA2 718/4885CA7 141/4885 |
| US-20210292313-A1 | SUBSTITUTED PHENAZINES AND METHODS OF TREATING CANCER AND BACTERIAL DISEASES | TLR5, TOP2A, SCN5A | CA1 3541/4885CA2 718/4885CA7 141/4885 |
| US-20160251320-A1 | Compounds | NISCH, MDN1, PIR | CA1 4461/4885CA2 4197/4885CA7 2227/4885 |
| US-11046678-B2 | Substituted phenazines and methods of treating cancer and bacterial diseases | NRAS, ABCB11, APC | CA1 3605/4885CA2 804/4885CA7 362/4885 |
| US-20200095237-A1 | COMPOUNDS | MSR1, CA7, SLC7A5 | CA1 208/4885CA2 170/4885CA7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.